RWIN - ETF AI Analysis
Top Page
Rayliant NxtGen Multifactor International Equity ETF (RWIN)
Rating:66Neutral
Price Target:―
Positive Factors
Broad International Diversification
The ETF spreads its investments across many countries, including Japan, the U.S., the UK, and several major European markets, which helps reduce reliance on any single economy.
Strong Performance From Key Holdings
Several of the largest positions, such as ASML, Advantest, Dai-ichi Life, Power Corp of Canada, and Rio Tinto, have shown strong gains this year, supporting the fund’s overall results.
Multi-Sector Exposure
Holdings are spread across financials, health care, technology, consumer sectors, and more, which can help smooth out returns when one industry is struggling.
Negative Factors
Small Asset Base
The fund manages a relatively low amount of money, which can sometimes mean less trading liquidity for investors.
Mixed Performance Among Top Holdings
Not all major positions are doing well, with at least one large holding showing weak performance this year, which can drag on the ETF’s returns.
Moderate Expense Ratio
The fund’s fees are not especially low, so costs may take a noticeable bite out of long-term returns compared with cheaper index ETFs.
RWIN vs. SPDR S&P 500 ETF (SPY)
AUM1.99M
RegionDeveloped Markets
Expense Ratio0.42%
Beta0.70
IssuerRayliant
Inception DateApr 07, 2026
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume204
30 Day Avg. Volume477
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
30.78Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering171
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RWIN Summary
Rayliant NxtGen Multifactor International Equity ETF (RWIN) is an actively managed fund that invests in a wide mix of companies in developed markets outside the U.S., such as Japan, the UK, and Europe. It follows a multifactor, “next generation” international equity theme, aiming to pick higher-quality stocks across many sizes and sectors. Well-known holdings include ASML Holding and Roche. Someone might invest in RWIN to diversify beyond U.S. stocks while spreading money across many industries and countries. A key risk is that international stock prices can rise and fall significantly with global market and currency swings.
How much will it cost me?This ETF has an expense ratio of 0.42%, which means you’ll pay about $4.20 per year for every $1,000 you invest. That’s higher than the cost of a typical low-cost index ETF because this fund is actively and quantitatively managed, aiming to add value by carefully selecting and weighting international stocks.
What would affect this ETF?RWIN could benefit if developed markets outside the U.S. grow steadily, especially if financials, health care, and technology companies like Roche, ASML, and major insurers continue to perform well and global interest rates stabilize or fall, supporting stock prices. On the other hand, slower economic growth abroad, rising interest rates that pressure financial firms, or new regulations affecting big international companies could hurt returns, and the fund’s active, multifactor approach may lag simple market indexes in certain market environments.
RWIN Top 10 Holdings
RWIN’s story is driven by a mix of global blue chips, with a clear tilt toward non-U.S. tech, health care, and financials. ASML is the star of the show, rising strongly and giving the fund a powerful semiconductor engine, while Advantest has cooled off lately, taking a bit of shine off that theme. On the defensive side, Roche has been lagging, acting more like a brake than a booster. European insurers like AXA and Allianz, along with Canada’s Power Corp and Australia’s Rio Tinto, are steady contributors, underscoring the fund’s broad developed-markets ex-U.S. reach.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Roche Holding AG | 2.96% | $58.00K | $315.55B | 23.56% | 73 Outperform | |
| Advantest | 2.95% | $57.84K | ¥22.14T | 123.51% | 75 Outperform | |
| ASML Holding NV | 2.25% | $44.12K | €633.25B | 151.49% | 76 Outperform | |
| AXA SA | 2.18% | $42.82K | €87.48B | 1.40% | 75 Outperform | |
| Allianz | 1.99% | $39.05K | €151.63B | 19.27% | 67 Neutral | |
| SAFRAN SA | 1.78% | $34.97K | €137.33B | 27.22% | 67 Neutral | |
| Dai-ichi Life Holdings | 1.63% | $32.03K | ¥6.67T | 46.27% | 69 Neutral | |
| ― | 1.61% | $31.56K | ― | ― | ― | |
| Galderma Group AG | 1.59% | $31.16K | CHF40.48B | 56.06% | 70 Outperform | |
| Power Corp of Canada | 1.55% | $30.40K | C$55.67B | 64.79% | 76 Outperform |
RWIN Technical Analysis
Positive
―
Price Trends
26.14
Positive
Market Momentum
0.07
Positive
52.60
Neutral
39.10
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RWIN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 26.26, equal to the 50-day MA of 26.14, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 52.60 is Neutral, neither overbought nor oversold. The STOCH value of 39.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RWIN.
RWIN Peer Comparison
Comparison Results
Performance Comparison
RWIN
Rayliant NxtGen Multifactor International Equity ETF
26.37
0.47
1.81%
INEQ
Columbia International Equity Income Etf
―
―
―
TISC
Thrivent International Small Cap ETF
―
―
―
FFDI
Fidelity Fundamental Developed International ETF
―
―
―
TXUG
Thornburg International Growth Fund ETF
―
―
―
FHIL
Federated Hermes International Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents